Royalty Pharma plc
Royalty Pharma plc scores highest on Nitro (95) and lowest on Price (32). Its PosiPenta is 70.37 out of 100, better than most similar companies.
On the Penta Grid this week, Royalty Pharma plc is Grid #19 of 837 in the Healthcare sector in United States, and Grid #45 of 4,000 in United States.
Compared with similar companies in the Healthcare sector in United States.
The five pillars
Similar companies
| Company | PosiPenta | P | E | N | T | A |
|---|---|---|---|---|---|---|
| Royalty Pharma plc | 70.37 | 32 | 89 | 95 | 53 | 83 |
| Biogen Inc. | 69.41 | 43 | 91 | 96 | 56 | 61 |
| ResMed Inc. | 66.32 | 42 | 69 | 83 | 70 | 68 |
| Centene Corporation | 54.38 | 33 | 48 | 97 | 45 | 50 |
| Zoetis Inc. | 54.09 | 45 | 60 | 46 | 52 | 67 |
| Revolution Medicines, Inc. | 40.04 | 5 | 27 | 83 | 34 | 51 |
Similar-sized companies in the same sector, this week. P Price · E Earnings · N Nitro · T Torque · A Anchor.
Details
PPrice
| P/E ratio | 32.43 |
| P/B ratio | 5.16 |
EEarnings
| Trailing EPS | ₹178.06 |
| Forward EPS | ₹549.26 |
NNitro
| Price | 5773.82 |
| 52-week high | 6097.75 |
| 52-week low | 3401.69 |
| Fall from 52-week high | 5.3% |
TTorque
| Return on equity (ROE) | 13.96% |
| Debt-to-equity | 0.92 |
AAnchor
| Beta (price swings) | 0.41 |
| Market cap | ₹3,33,632 Cr |
| Insider holding | 6.49% |
| Dividend yield | 1.58% |
Figures as used for the week of 17 Oct 2026; today's figures on the company page may differ slightly.
Questions
What is Royalty Pharma plc's PosiPenta score?
Royalty Pharma plc's PosiPenta is 70.37 out of 100 for the week of 17 Oct 2026, based on 5 of 5 pillars.
Where does Royalty Pharma plc stand on the Penta Grid?
On the Penta Grid this week, Royalty Pharma plc is Grid #19 of 837 in the Healthcare sector in United States, and Grid #45 of 4,000 in United States.
Which PosiPenta pillar is strongest for Royalty Pharma plc?
Nitro (momentum), with a score of 95 out of 100: much better than most similar companies.
Which PosiPenta pillar is weakest for Royalty Pharma plc?
Price (valuation), with a score of 32 out of 100: weaker than most similar companies.
Has Royalty Pharma plc's PosiPenta changed since last week?
Yes, it rose 10.56 points, from 59.81 to 70.37.
PositoAI is for research and education only and is not investment advice.